SEC Form 4 · accession 0001209191-17-058428
CELGENE CORP /DE/ · CELG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Terrie Curran
Officer — See remarks
Period of report
Oct 30, 2017
Accepted (ET)
Oct 31, 2017 · 4:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000816284
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $100.97 | Oct 30, 2017 | A | 15,659 | A | — | Oct 30, 2027 | Common Stock | 15,659 | 15,659 | D |
| Restricted Stock UnitF5,F3,F4 | — | Oct 30, 2017 | A | 1,857 | A | — | — | Common Stock | 1,857 | 1,857 | D |
Explanation of responses
- F1Option is immediately exercisable and will vest in four equal annual installments, commencing on October 30, 2018.
- F2The option was issued pursuant to the Company's 2017 Stock Incentive Plan.
- F3Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
- F4The restricted stock units will fully vest on October 30, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date.
- F5The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan.
Remarks
President, Inflammation & Immunology